Penile Cancer Survival Rate
The penile cancer survival rate – especially for cancers that are detected in their earliest stages – is relatively high. The majority of men who are diagnosed with stage 1 or 2 penile cancer survive for at least five years after their diagnosis, with many living long and healthy lives. And, as a result of recent advances in treatment, most patients don’t have to sacrifice their reproductive abilities, sexual sensation or urinary function for a better chance at survival.
Several factors can contribute to a patient’s individual outcome. For instance, men who report symptoms to their doctor as soon as they occur, leading to an early diagnosis, often have better survival rates. Other factors that can improve a patient’s personal prognosis include:
-
Seeking treatment at a high volume cancer center such as Moffitt Cancer Center. Penile cancers are particularly rare in the United States; many oncologists have never treated such a malignancy. Moffitt has extensive experience with even the least commonly diagnosed cancers.
-
Accessing the newest developments in treatment. At one point, the only treatments available to men with penile cancer were surgery, chemotherapy and radiation therapy. Now, patients can benefit from novel therapies, such as radiosensitizers and biological therapies. At Moffitt, we offer a complete range of treatment options in a single, convenient location, and help our patients access the most cutting-edge therapies through our extensive clinical trials.
-
Working with a collaborative treatment team. When multiple experts come together to treat a patient, the benefits compound as well. At Moffitt, a multispecialty team of surgeons, medical oncologists, radiation oncologists, urologists and supportive care professionals all work together to review the patient’s progress during weekly tumor board meetings.
To learn more about the penile cancer survival rate, call 1-888-663-3488 or submit a new patient registration form online. Referrals are not required to meet with our expert oncologists.